Health TrialsbyHealthPanel

Systems Oncology Approach to Optimize Ovarian Cancer Treatment

ConditionOvarian Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorUniversity of Helsinki

About this trial

The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients diagnosed with ovarian cancer

Available tumor tissue/blood samples

Disqualifiers

Inability to consent to the study

Trial population

All ovarian cancer patients who give their informed consent to the study.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Biomolecular profiling

    Genetic

    Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Recruitment and collection of real-world clinical data from ovarian cancer patients

Prospective recruitment and collection of clinical data from 500 ovarian cancer patients. Fraction of patients from which the collection of clinical data including patient age, tumor stage, histological diagnoses have been collected.

Time frame
5 years
2

Successful collection and translational analysis of biospecimens

Fraction of the recruited patients, from which tumor, ascites, and/or peripheral blood samples that have been successfully collected and subjected to molecular profiling.

Time frame
5 years

Secondary outcomes

1

Discovery of candidate prognostic and predictive biomarkers

Number of clinical and/or molecular features which of statistically significantly correlate to patient treatment outcomes (response to chemotherapy by RECIST1.1, Progression Free survival, Overall Survival).

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Helsinki

Lead sponsor

Helsinki University Central Hospital

Collaborator

Source ClinicalTrials.gov
Apply now